Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

Dr. Frank Hensel

Principal

About me

Team Life Sciences & Chemistry
at HTGF since 2015
my focus Drug development
my background PhD in biology, founder of a biotech company

CV

Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio 3 companies already entered the clinical stage and one company, Amal therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to 425Mio. €

Four questions for …

What has been your most important milestone so far?

Dr. Frank Hensel

Having founded a startup myself and having gone through all the ups and downs with it over years.

What fascinates you about pre-seed/seed phases?

Dr. Frank Hensel

You can still move and structure a lot in the seed sector. No two cases are the same and every investment is a new challenge.

What do you like most about your job?

Dr. Frank Hensel

Interaction with great scientists and interesting technologies that can be provided to patients through collaboration with investors.

What inspires you outside of work?

Dr. Frank Hensel

A few hours on the racing bike clear your head and give you time to think.

Social Media & contact

My success stories in the HTGF portfolio

12 of 500 Companies
2021

WMT

Oncology

WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …

To the complete profileof WMT
2020

Tubulis

Oncology

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …

To the complete profileof Tubulis
2016

SciRhom

Immunology

SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge …

To the complete profileof SciRhom
2019

Abalos

Oncology

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer …

To the complete profileof Abalos
2019

Tacalyx

Oncology

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …

To the complete profileof Tacalyx
2019

Alentis

Metabolic Diseases

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …

To the complete profileof Alentis
2017

PerformaNat

Agriculture, Agritech & Animal Health

PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy …

To the complete profileof PerformaNat
2016

HepaRegeniX

Metabolic Diseases

Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …

To the complete profileof HepaRegeniX
2015

Computomics

Food, Nutrition & Personal Care

Computomics is a spin-off of the University of Tübingen and the Max Planck Institute for Developmental Biology. Computomics was founded in 2012, when it became clear that a breakthrough in …

To the complete profileof Computomics
2012

ALGIAX

Pain

Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.

To the complete profileof ALGIAX

Guided to exit

12 of 500 Companies
2017

CARDIOR

Exit
Cardiology / Cardiovascular

Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …

To the complete profileof CARDIOR
2017

KSK Diagnostics

Exit
Life Sciences

KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …

To the complete profileof KSK Diagnostics
2013

CCI Custom Cells Itzehoe

Exit
Chemistry

Custom Cells manufactures customer-specific acculumators and intermediate products based on lithium technology.

To the complete profileof CCI Custom Cells Itzehoe
2014

Amal Therapeutics

Exit
Life Sciences

Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic …

To the complete profileof Amal Therapeutics

Recent posts

Last update 2 days ago
Zum Artikel

News

15. April 2025

HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration

Zum Artikel

Story

27. February 2025

Innovation, Investments, Impact: A Look Back at HTGF’s Biotech Year 2024

Zum Artikel

Story

27. August 2024

Against the tide – HTGF portfolio SciRhom company rewarded for courage with EUR 63 million Series A financing

Zum Artikel

News

10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Zum Artikel

News

9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

Zum Artikel

News

25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals